U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07002346) titled 'INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma' on May 20.
Brief Summary: The goal of this clinical trial is to learn if QL1706 combined with bevacizumab can effectively treat adult female patients (18 to <75 years old) with newly diagnosed FIGO stage IC-IV advanced ovarian clear cell carcinoma. The main questions it aims to answer are:
1. Does QL1706 combined with bevacizumab, compared to platinum-based chemotherapy, prolong patients' progression-free survival (PFS)?
2. What is the safety profile of QL1706 combined with bevacizumab, such as what medical problems (adverse events) d...